Traduction de «SP » (Français → Anglais) :

Committee of Experts on Blood Transfusion and Immunohaematology | SP-HM [Abbr.]

secondary progressive multiple sclerosis | SPMS | relapsing progressive multiple sclerosis | RPMS | relapsing/progressive multiple sclerosis | RP multiple sclerosis

magic flower sp. blue [ Achimenes sp. blue ]

Strategic Project Grants [ SPG | Strategic Project Grants Program | SPG Program ]

athlete with multiple sclerosis [ multiple sclerosis athlete | MS athlete ]

Inf FLUZONE High-Dose SP

paradoxical sleep | rapid eye-movement sleep | REM sleep | REMS [Abbr.]

Centre Party | Sp [Abbr.]

REM sleep | desynchronized sleep | paradoxical sleep | rapid eye movement sleep

Fusarium oxysporum f. sp. albedinis (Kilian et Maire) Gordon

...r each site, and how is consistency in diagnosis and treatment being ensured across sites; (e) who is performing the diagnoses for CCSVI for each site, (i) how is the diagnosis being performed, including, but not limited to, ultrasound and venogram, (ii) how many diagnoses has each person undertaking the diagnosis at each site performed prior to the study, and by whom was each person trained; (f) who is performing the procedures for each site, (i) how is the procedure being performed, including, but not limited to, anesthetic, balloon size, (ii) how many procedures has each person undertaking the procedure at each site performed prior to the study, and by whom was each person trained; (g) what are the selection criteria for the trial, ...[+++] including, but not limited to, type of MS, Expanded Disability Status Scale (EDSS) score, venous abnormality/malformed valve/stenosis, mobility, (i) how do these criteria compare with the international literature, (ii) with how many international studies to date will the selection criteria be analytically comparable; (h) if both progressive and relapsing-remitting forms of MS are to be examined in the trial, how will statistical significance be ensured given that 50 of 100 patients will undergo a “sham” procedure, 25 patients will have a progressive form of the disease, and 25 will have a relapsing-remitting form of the disease, and will people with both primary progressive and secondary progressive forms of the disease be included, and if so, how will statistical significance be ensured; (i) given that research has shown numerous venous abnormalities in the head, neck, and chest of MS patients, (i) how will statistical significance be ensured if there are only a limited number of patients, but multiple types of venous or valvular abnormality, (ii) how will a venous stenosis be measured (e.g. diameter, size); (j) what outcomes will be measured, including, but not limited to, EDSS, Modified Fatigue Impact Scale, Multiple Sclerosis Impact Scale, and Multiple Sclerosis Quality of Life Inventory, and at what time scales; (k) will patient-reported quality of life scores be included, and if so, what is the specific methodology; (l) what specific follow-up care will patients undergoing the “sham” procedure and treatment receive, and at what specific time periods; (m) if patients received the “sham” procedure, within what time period will they receive treatment; (n) how will the results of this study be interpreted within the growing international body of research, (i) to how many studies will this study be compa ...

15. Considers that the FTA should respect sensitivities linked to trade in agricultural and fisheries products, but that this should not prevent the mutual opening of markets in sectors of complementarity, and emphasises that new market access must be subject to the thorough enforcement of intellectual property protection, also covering geographical indications, including marks of origin for agricultural and foodstuff products, as well as sanitary and phytosanitary measures (SPS), in the interests of producers and consumers; insists that nothing in the agreement must hamper access to affordable generic medicines;

16. Considers that the FTA should respect sensitivities linked to trade in agricultural and fisheries products, but that this should not prevent the mutual opening of markets in sectors of complementarity, and emphasises that new market access must be subject to the thorough enforcement of intellectual property protection, also covering geographical indications, including marks of origin for agricultural and foodstuff products, as well as sanitary and phytosanitary measures (SPS), in the interests of producers and consumers; insists that nothing in the agreement must hamper access to affordable generic medicines;